Aligos Therapeutics (ALGS) Cash & Current Investments (2019 - 2026)

Aligos Therapeutics (ALGS) has 8 years of Cash & Current Investments data on file, last reported at $79.8 million in Q1 2026.

• Quarterly Cash & Current Investments fell 42.16% year-over-year to $79.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.8 million (down 42.16% YoY) and the FY2025 annual result came in at $18.4 million, down 67.66% from the prior year.
• Cash & Current Investments improved to $79.8 million in Q1 2026, from $18.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $227.2 million in Q2 2025 to a low of $18.4 million in Q4 2025.
• A 5-year average of $105.0 million and a median of $94.6 million in 2024 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 140.23% in 2025, down 67.66% in 2025.
• Tracing ALGS's Cash & Current Investments over 5 years: stood at $125.8 million in 2022, then grew by 7.93% to $135.8 million in 2023, then slumped by 58.07% to $56.9 million in 2024, then plunged by 67.66% to $18.4 million in 2025, then surged by 333.55% to $79.8 million in 2026.
• The last three Cash & Current Investments figures came in at $79.8 million (Q1 2026), $18.4 million (Q4 2025), and $99.2 million (Q3 2025), per Business Quant data.